These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
If you normally inject on Saturday and want to inject on Friday instead, you are shortening your interval from 168 hours to approximately 144 hours
Missing doses or taking them erratically can lessen their effectiveness and make side effects worse
There are no retail locations, and the platform is not available through third-party pharmacies or marketplaces
GLP-1 (Glucagon-like peptide-1) injections are a class of medications that mimic the action of the natural GLP-1 hormone in the body, stimulating insulin secretion, suppressing appetite, and delaying gastric emptying, thereby promoting weight loss
Yes, transitioning between weekly shots and daily oral weight loss medication is clinically possible
